CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 0.89 USD 2.71% Market Closed
Market Cap: 69.7m USD
Have any thoughts about
CytomX Therapeutics Inc?
Write Note

CytomX Therapeutics Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CytomX Therapeutics Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
CytomX Therapeutics Inc
NASDAQ:CTMX
Total Other Income
-$11k
CAGR 3-Years
54%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Other Income
-$4.6B
CAGR 3-Years
12%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Total Other Income
$302m
CAGR 3-Years
76%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Total Other Income
$578m
CAGR 3-Years
81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Other Income
-$68m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Other Income
$6m
CAGR 3-Years
-49%
CAGR 5-Years
-35%
CAGR 10-Years
8%
No Stocks Found

CytomX Therapeutics Inc
Glance View

Market Cap
69.6m USD
Industry
Biotechnology

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).

CTMX Intrinsic Value
1.18 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is CytomX Therapeutics Inc's Total Other Income?
Total Other Income
-11k USD

Based on the financial report for Sep 30, 2024, CytomX Therapeutics Inc's Total Other Income amounts to -11k USD.

What is CytomX Therapeutics Inc's Total Other Income growth rate?
Total Other Income CAGR 5Y
41%

Over the last year, the Total Other Income growth was 73%. The average annual Total Other Income growth rates for CytomX Therapeutics Inc have been 54% over the past three years , 41% over the past five years .

Back to Top